Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence?

Archives of Iranian Medicine

Volumn 16, Issue 4, 2013, Pages 208-212

  Mohamadkhani, Ashraf ^a   Moghaddam, Sodaif Darvish ^b   Salmanroghani, Hassan ^c   Allafsghari, Amin ^d   Yazdanbod, Abbas ^d   Mirzaei, Mahboobeh ^a   Haj Sheykholeslami, Arghavan ^a   Bashiri, Jafar ^d   Sadjadi, Alireza ^a   Massarrat, Sadegh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c YAZD UNIVERSITY   (Iran)

^d ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biomarker; Gastric cancer; Pepsinogen I; Pepsinogen II

Indexed keywords

PEPSINOGEN I; PEPSINOGEN II;

ADULT; ARTICLE; ATROPHIC GASTRITIS; CANCER INCIDENCE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL ENDOSCOPY; GEOGRAPHIC DISTRIBUTION; HELICOBACTER INFECTION; HUMAN; INFECTION RATE; IRAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; STOMACH NEOPLASMS;

EID: 84875352995     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology. 1973; 65: 36 -42.
2. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology. 1982; 83: 204 -209.
3. Samloff IM. Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology. 1982; 82: 26 -33.
4. iki K, Ichinose M, Kakei N, Yahagi N, Matsushima M, Tsukada S, et al. The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Adv Exp Med Biol. 1995; 362: 139 -143.
5. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999; 44: 693 -697.
6. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol. 2006; 163: 629 -637.
7. Miki K, Fujishiro M, Kodashima S, Yahagi N. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc. 2009; 21: 78 -81.
8. Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, Rafiee R, Shahidi SM, Nikbin B, et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol. 2008; 6: 174 -179.
9. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a highrisk region of China: a randomized controlled trial. JAMA. 2004; 291: 187 -194.
10. Cheung TK, Wong BC. Treatment of Helicobacter pylori and prevention of gastric cancer. J Dig Dis. 2008; 9: 8 -13.
11. Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, et al. Cancer occurrence in Ardabil: results of a population -based cancer registry from Iran. Int J Cancer. 2003; 107: 113-118.
12. Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J Clin Pathol. 2004; 57: 37 -42.
13. Sipponen P, Ranta P, Helske T, Kaariainen I, Maki T, Linnala A, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol. 2002; 37: 785 -791.
14. Knight T, Wyatt J, Wilson A, Greaves S, Newell D, Hengels K, et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer. 1996; 73: 819 -824.
15. Sadjadi A, Zahedi M, moghadam SD, Nouraie M, Alimohammadian M, Ghorbani A, et al. The first population-based cancer survey in Kerman Province of Iran. Iranian J Publ Health. 2007; 36: 26 -34.
16. Iranian Annual of National Cancer Registration Report 2006-2007. Ministry of Healt and Medical Education, Islamic Republic Iran.
17. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52: 6735 -6740.
18. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009; 151: 121 -128.
19. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24: 1587 -1600.
20. Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006; 55: 1545 -1552.
21. Peleteiro B, Carrilho C, Modcoicar P, Cunha L, Ismail M, Guisseve A, et al. Chronic atrophic gastritis, Intestinal Metaplasia, Helicobacter pylori Virulence, IL1RN polymorphisms, and smoking in dyspepsic patients from Mozambique and Portuga. Helicobacter. 2009; 14: 306 -308.
22. Carrilho C, Modcoicar P, Cunha L, Ismail M, Guisseve A, Lorenzoni C, et al. Prevalence of Helicobacter pylori infection, chronic gastritis, and intestinal metaplasia in Mozambican dyspeptic patients. Virchows Arch. 2009; 454: 153 -160.
23. Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome, and constipation in two populations in Iran. Eur J Gastroenterol Hepatol. 1995; 7: 427 -433.
24. Nouraie M, Latifi-Navid S, Rezvan H, Radmard AR, Maghsudlu M, Zaer-Rezaii H, et al. Childhood hygienic practice and family education status determine the prevalence of Helicobacter pylori infection in Iran. Helicobacter. 2009; 14: 40 -46.
25. Stemmermann GN, Ishidate T, Samloff IM, Masuda H, Walsh JH, Nomura A, et al. Intestinal metaplasia of the stomach in Hawaii and Japan. A study of its relation to serum pepsinogen I, gastrin, and parietal cell antibodies. Am J Dig Dis. 1978; 23: 815 -820.
26. Genta RM, Pusztaszeri M. The gastric mucosa in gastric cancer patients in a low-incidence area. Eur J Gastroenterol Hepatol. 2006; 18: 1085 -1093.
27. Kekki M, Samloff IM, Varis K, Ihamaki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl. 1991; 186: 109 -116.
28. Ricci C, Vakil N, Rugge M, Gatta L, Perna F, Osborn JF, et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol. 2004; 99: 1910 -1915.
29. Sitas F, Smallwood R, Jewell D, Millard PR, Newell DG, Meuwissen SG, et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev. 1993; 2: 119 -123.
30. Inoue M, Kobayashi S, Matsuura A, Hamajima N, Tajima K, Tominaga S. Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomarkers Prev. 1998; 7: 261 -263.
31. Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev. 2001; 10: 107 -112.